Logo image of ZLNA.OL

ZELLUNA ASA (ZLNA.OL) Stock Price, Forecast & Analysis

Europe - Euronext Oslo - OSL:ZLNA - NO0013524942 - Common Stock

14.8 NOK
0 (0%)
Last: 1/20/2026, 7:00:00 PM

ZLNA.OL Key Statistics, Chart & Performance

Key Statistics
Market Cap374.44M
Revenue(TTM)5.00K
Net Income(TTM)-212.87M
Shares25.30M
Float12.41M
52 Week HighN/A
52 Week LowN/A
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-38.7
PEN/A
Fwd PEN/A
Earnings (Next)02-12
IPO2019-06-03
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
ZLNA.OL short term performance overview.The bars show the price performance of ZLNA.OL in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30

ZLNA.OL long term performance overview.The bars show the price performance of ZLNA.OL in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of ZLNA.OL is 14.8 NOK. In the past month the price increased by 32.14%.

ZELLUNA ASA / ZLNA Daily stock chart

ZLNA.OL Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to ZLNA.OL.


Chartmill TA Rating
Chartmill Setup Rating

ZLNA.OL Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ZLNA.OL. While ZLNA.OL has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ZLNA.OL Financial Highlights

Over the last trailing twelve months ZLNA.OL reported a non-GAAP Earnings per Share(EPS) of -38.7. The EPS increased by 10.78% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -269.09%
ROE -337.63%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%74.69%
Sales Q2Q%N/A
EPS 1Y (TTM)10.78%
Revenue 1Y (TTM)N/A

ZLNA.OL Forecast & Estimates

9 analysts have analysed ZLNA.OL and the average price target is 25.5 NOK. This implies a price increase of 72.3% is expected in the next year compared to the current price of 14.8.


Analysts
Analysts42.22
Price Target25.5 (72.3%)
EPS Next Y89.02%
Revenue Next YearN/A

ZLNA.OL Ownership

Ownership
Inst Owners15.42%
Ins Owners0.72%
Short Float %N/A
Short RatioN/A

ZLNA.OL Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ARGX.BR ARGENX SE 64.25 42.14B
1AE.DE ARGENX SE 64.66 42.20B
22UA.DE BIONTECH SE-ADR N/A 21.65B
ABVX.PA ABIVAX SA N/A 8.13B
2X1.DE ABIVAX SA N/A 8.11B
GXE.DE GALAPAGOS NV N/A 1.88B
GLPG.AS GALAPAGOS NV N/A 1.86B
6IV.DE INVENTIVA SA N/A 1.05B
IVA.PA INVENTIVA SA N/A 985.65M
NANO.PA NANOBIOTIX N/A 838.95M
PHIL.MI PHILOGEN SPA 18.51 616.96M
FYB.DE FORMYCON AG N/A 400.23M

Related stock screener links

About ZLNA.OL

Company Profile

ZLNA logo image Zelluna ASA is a biotechnology company focused on developing innovative and cost-efficient therapies for advanced solid cancers. The company is headquartered in Oslo, Oslo and currently employs 26 full-time employees. The company went IPO on 2019-06-03. The firm develops cell therapies for the treatment of cancer patients. Zelluna ASA deals with eliminate solid cancers by unleashing thel elements of the immune system through pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell therapies. The firm provides benefit to patients, their families and all those around them, by developing therapies that bring together TCR guidance with the effector functions of allogeneic NK cells (TCR-NK) deploying a mechanism of action that has the potential to be both safe and potent. Zelluna ASA operates worldwide.

Company Info

ZELLUNA ASA

Ullernchausseen 64

Oslo OSLO NO

Employees: 26

ZLNA Company Website

ZLNA Investor Relations

Phone: 4741380080

ZELLUNA ASA / ZLNA.OL FAQ

What does ZELLUNA ASA do?

Zelluna ASA is a biotechnology company focused on developing innovative and cost-efficient therapies for advanced solid cancers. The company is headquartered in Oslo, Oslo and currently employs 26 full-time employees. The company went IPO on 2019-06-03. The firm develops cell therapies for the treatment of cancer patients. Zelluna ASA deals with eliminate solid cancers by unleashing thel elements of the immune system through pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell therapies. The firm provides benefit to patients, their families and all those around them, by developing therapies that bring together TCR guidance with the effector functions of allogeneic NK cells (TCR-NK) deploying a mechanism of action that has the potential to be both safe and potent. Zelluna ASA operates worldwide.


Can you provide the latest stock price for ZELLUNA ASA?

The current stock price of ZLNA.OL is 14.8 NOK.


Does ZLNA stock pay dividends?

ZLNA.OL does not pay a dividend.


What is the ChartMill technical and fundamental rating of ZLNA stock?

ZLNA.OL has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


What is the Price/Earnings (PE) ratio of ZELLUNA ASA (ZLNA.OL)?

ZELLUNA ASA (ZLNA.OL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-38.7).


What is the employee count for ZLNA stock?

ZELLUNA ASA (ZLNA.OL) currently has 26 employees.


Who owns ZELLUNA ASA?

You can find the ownership structure of ZELLUNA ASA (ZLNA.OL) on the Ownership tab.